Advanced search
Show most relevant results first | Most recent results are first | Show use by person

Results 1-2 of 2 for drugs segment:8693501

Written Answers — Department of Health: Medicinal Products (20 Sep 2023)

Jennifer Murnane O'Connor: 988. To ask the Minister for Health the considerations that his Department is giving to the inclusion of the drugs saxenda and ozempic, both now recognised as valuable medications in the treatment of obesity, to the drugs payment scheme or medical card scheme for non-diabetic patients; if there are plans to widen the prescription of saxenda and ozempic to medical card holders with a BMI of...

Written Answers — Department of Health: Medicinal Products (20 Sep 2023)

Stephen Donnelly: ...(NCPE). I, as the Minister for Health, have no role in these decisions. Saxenda (Liraglutide) 6 mg/ml solution has been made available for reimbursement support under the community drug schemes on a managed access basis since 1st January 2023. The HSE Medicines Management Programme (MMP) developed a Managed Access Protocol (MAP) for Saxenda (Liraglutide). The relevant circular can be...

   Advanced search
Show most relevant results first | Most recent results are first | Show use by person